Neurocrine Biosciences | NBIX - 流動負債





流動負債 変化する 日付
AbbVie USD 42.1B 1.19B 2026-03
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Cytokinetics USD 199.18M 3.27M 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Exelixis USD 370.98M 34.67M 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Prothena USD 32.52M 8.33M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Repligen USD 126.21M 9.62M 2026-03
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Teva Pharmaceutical Industries USD 13.53B 76M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03
Xoma USD 28.3M 6.81M 2025-09